FDA
-
-
-
-
-
-
-
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
-
-
-
-
-
-
RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11
-
-
-
-
-
-
-
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
-
-
-
-
-
-
-
RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'
-
-
-
-
-
-
-
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
-
-
-
-
-
-
-
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
-
-
-
-
-
-
-
uniQure faces securities lawsuit after FDA approval delay causes 49% drop
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

